Analyzing the annual DDDs of EPO indicated that the low-, medium- and high-dose groups exhibited reduced dementia rates compared with the non-EPO cohort, suggesting a reduction of risk for annual various DDDs of EPO <200. This evidence concerns the gene EPO and dementia.